TOPICS TO BE PRESENTED AND DISCUSSED
Blood pressure measurements
• Reproducibility of WUCH and MUCH
• Night-time HBPM
• Advantages and shortcomings of different devices (non-invasive finger beat-to-beat, wrist-cuff, hybrid manual auscultatory…)
• Is there any room for non-attended blood pressure measurements?
• Blood pressure variability
• Blood pressure measurements for patients undergoing haemodialysis.
Special hypertension phenotypes
• Isolated night time hypertension – evaluation and therapy
• Orthostatic and supine hypertension
• Transition period from adolescents to adulthood
• Young adults – how to treat them (where is the evidence)? - How to determine global risk ?
• Isolated diastolic hypertension – to treat or not to treat? One entity or several subtypes?
• Biological age – could it be clinical useful?
• Sex/gender differences – how important it is in every day clinical work?
• Could obesity be considered as a secondary form of hypertension?
Hypertension beyond cardiovascular system
• Inflammatory diseases, chronic infections, and hypertension
• NASH and hypertension
• COPD and hypertension
• Depression and psychosocial factors
• Oncohyperetensiology – it is time to educate oncologists
• Glaucoma and hypertension
• Air pollution, noise, and climate changes – environmental hypertensiology
• Gut microbiota – foe or friend?
New diagnostic options
• Kidney biomarkers
• Cardiac enzymes
• miRNAs
• How to determine salt sensitivity
• Could we rely on 24-hour central blood pressure measurements?
• Which new biomarkers are optimal for prediction of pre-eclampsia?
• Albuminuria – important "small" factors with significant impact on the result
Cardiology
• LVH and Hypertensive Cardiomyopathy
• Coronary artery disease
• Diastolic heart failure
• Optimal treatment of LVH regression
• Evaluation of Cardiac damage in hypertensive patients
• Novelties in Cardiovascular disease diagnosis
and treatment.
Pharmacology and Nursing
• Opportunistic screening for hypertension
• Education on adherence, life style…
• Role in the follow up.
• How to organize a network – pharmacist-nurse-GP-hypertension specialist
IMPORTANT DEADLINES
ABSTRACT SUBMISSION
1.7-20.9.2023
REGISTRATION
1.7-10.9.2023
LATE REGISTRATION
11.9-11.10.2023
WORKSHOP REGISTRATION
TBD
Adherence and clinical inertia
• Which method should be used for detection of non-adherence in routine clinical work?
• How to manage non-adherence?
• How to manage clinical inertia?
• How to increase patient’s empowerment?
• Artificial intelligence and smartphone applications
Treatment – recommendation and novelties
• Could we tailor antihypertensive therapy based on HBPM? What is true clinical (practical) value of HBPM?
• When to use nitrates in hypertensive patient?
• ACE inhibitors or sartans? Which class to prefer? Or when?
• Are sartans slowing dementia?
• ARNi in hypertension – what is the difference between Japan and Europe?
• Shall we consider sequential nephron blockade more frequently?
• What is the new evidence which upgraded beta blockers?
• How to follow and treat hypertensive patients whom BP was achieved?
• How to treat hypertensive patients in stage 1? Do we have enough evidence?
• Treatment of octogenarians? Is the indapamide (the only) drug of choice?
• Is it important which drug should be used for hypertension treatment in acute stroke?
• Could statins/PCSK9 inhibitors be used for secondary prevention after haemorrhagic stroke?
• Drug(s) of choice in ISHY
• Can we use urapidil and eplerenone in pregnancy?
• Could thiazide like diuretics be used when eGFR is below 25 ml/min?
• NOAKs and chronic kidney disease
• Optimal treatment of hypertension after kidney transplantation
• How to delay the progression of chronic kidney disease?
• Could obesity be considered as a secondary form of hypertension?
• Atherosclerotic renovascular hypertension – update on diagnosis and treatment
• When to use intervention in hypertensive patient with fibromuscular dysplasia
• Is resistant hypertension only indication for renal denervation? Cost? Feasibility?
• New drugs – new promises?
• Shall we treat asymptomatic hyperuricemia? Is uric acid an independent cardiovascular risk factor or not?
